Wonderful. Thank you, Megan, and thank you all for joining. As Megan mentioned, I'll provide some background, uh, discuss the case for using Angiotensin II type 2 receptor agonists. Then I'll talk about the Phase 2b ASPIRE trial that we've announced today that we've initiated. I'll turn it over to Hans to talk a little bit about the transaction. We've also announced the structure today, and then we'll be very happy to take questions via phone and via chat as well. So at the outset, right, just to recap really on what we're trying to achieve at the core and what we're spending as a high priority, in terms of our time, our resources, and our efforts, is the advancement of buloxibutid, a potentially transformational therapy for IPF? Uh, moving forward towards, you know, approval. And I think the case comes in three pillars.
First is an upstream mechanism of action with an incredibly strong preclinical and translational data set. Buloxibutid has a mechanism that targets the source of the disease, where it agonizes and activates a tissue repair system in the alveolar epithelial stem or progenitor cells, allowing for the replenishment of the epithelium in the air sacs. Um, and this is quite distinct from the other ways of treating IPF that are seen in the standard of care and emerging standard of care, which focus solely on blocking the fibrosis further downstream. Instead, the Viper mechanism of action allows us to address both the injury at the center or the inception of the disease. You can then also have a resolution of the fibrosis further downstream. So that's really the first pillar of this case, and this disease-modifying mechanism that can repair the epithelium and resolve the fibrosis is then evident in the Phase 2b dataset where we've shown at 36 weeks the ability to improve lung function in IPF patients by over 200ml. And that's something that's quite tremendous and is consistent with this mechanism of action. You know, one question that many ask about anti-fibrotic or potential therapies for IPF is whether the effect will be sustained. And so to see over 36 weeks that you're able to have this effect on IPF patients is quite outstanding. And the consistency and robustness of the dataset is also quite outstanding. Most patients, 65%, have an improvement in lung function, whereas an untreated IPF patient would typically experience a decline in lung function by 180ml. All subgroups are performing above baseline at both mean and median, which is also really reflecting this robustness and consistency across the data set. And I think it's not to be understated that the drug has an excellent safety and tolerability profile. We do not see the gastrointestinal side effects associated with the standard of care and some of the emerging standards of care, such as nausea and diarrhea; furthermore, other side effects like photosensitivity are not present in the V4 molecule and mechanism of action. And I think that this is tremendous because it's something that allows this drug to behave as a frontline therapy for the disease state. It allows it to be combined if that's what's most suitable. And it's also a reflection of the difference between this mechanism and many of the other mechanisms that are pursued where blocking, you know, kind of downstream wound healing processes can also interfere with normal processes to maintain, uh, you know, tissue homeostasis and extracellular matrix. And by adopting a different approach focused on repair and resolution, you can achieve this in a very safe and well-tolerated way, according to the data available to date. And the third point I'll make about our Phase 2a dataset links it back to the first pillar; the biomarkers that we see in the Phase 2a dataset demonstrate the mechanism that we observe in our preclinical datasets. So we see in the IPF patients a trend of decrease in TGF-beta 1, which is a profibrotic cytokine that drives the production of new collagen and fibrosis. And then we also see a significant upregulation in the IPF patients in their blood of MMP-13, a matrix metalloprotease that is responsible for chopping up or digesting existing fibrosis. So basically, we're showing in our dataset biomarkers that suggest we're both stopping or slowing down new fibrosis buildup and getting rid of, digesting, or resolving fibrosis that already exists, which is quite excellent as well. And then the third pillar is really that this next experiment that we've now initiated, this Phase 2b, is the experiment. It is robust, featuring a regulatory or approval endpoint with a 52-week change in forced vital capacity. It is a large study with 270 patients for this patient population. A robust size, it is designed with the commercial label in mind, which is as a front-line therapy that can be combined with the standard of care, and it has a global footprint where we'll be enrolling this study from 14 different countries. So maybe from here I'll step forward and talk about the Phase 2b even a little bit more. Right. So I've mentioned the attributes that make us so excited about this, the robustness, the size. We've also sought to make it very patient-friendly and accessible, both because we want to be focused on ultimately serving the patients, but also because we want to ensure efficient enrollment. So we've really done our best to limit the number of in-person visits at clinical sites, making it easier for patients to participate, while also continuing to engage with the patients to ensure they are doing well in the study. And so we've included a number of virtual, phone, or video visits with the patients throughout the study as well. As I indicated, the robustness includes some dose-response testing where we'll be using the same dose level as in the Phase 2a, 100mg twice daily. But we'll also be exploring a lower dose, 50 mg twice daily, over that 52-week period. Uh, and then maybe if I could speak a little bit more about the powering as well. Right. What we saw in the Phase 2a, which is reflected in the graph on the left in green, is a 200 milliliter improvement in lung function, or over 200 milliliters, when you would expect a 180 milliliter decline in this patient population over 36 weeks. That's a 400 milliliter treatment effect, quite outstanding. What we saw in the Phase 2b, but actually, when we consider how we're powering the Phase 2b, we're doing so quite conservatively in the sense that we're powering the study to detect a stabilization of lung function up to 52 weeks. While it will be quite outstanding if we're able to observe an improvement in lung function, even a stabilization in lung function would both produce a positive clinical result and a blockbuster, multibillion-dollar commercial opportunity, in our view. Thus, it was important for us to power the study conservatively and robustly. And then, as we mentioned, we're targeting 14 countries, approximately 100 clinical sites. The sites are now coming online. As we mentioned, we've received regulatory approval to initiate this study from the US FDA, as well as from other health authorities, and we're looking forward to enrolling patients in due course. So maybe from here, I'll turn it over to Hans to talk a little bit about today's transaction as well.